Speaker(s): 

Adam Buchanan, MS, MPH, CGC- Director of Genomic Medicine, Geisinger (Has nothing to disclose) 

Christian Adonizio, MD, MLA, MBA, FACP-Physician of Hematology and Medical Oncology, Geisinger (Has nothing to disclose) 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Summarize two ways in which multi-cancer detection (MCD) tests are designed to detect cancer biomarkers in the blood.
• List three hereditary cancer syndrome-associated tumor types for which MCDs appear promising for surveillance.

   

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Adam Buchanan, MS, MPH, LCGC, Juliann Savatt, MS, LCGC, Melissa Kelly, MS, LCGC, Marc Williams, MD, and Cara McCormick, MPH have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None